Apr 16, 2020 - CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.
Apr 15, 2020 - AstraZeneca (AZN) to initiate enrollment in a clinical study to evaluate its blood cancer drug, Calquence, as a potential treatment for patients hospitalized with COVID-19 infection.
Apr 15, 2020 - Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.
Apr 14, 2020 - SNY vs. LLY: Which Stock Is the Better Value Option?
Apr 13, 2020 - Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
Apr 13, 2020 - Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.
Apr 11, 2020 - The pharma company believes that its rheumatoid arthritis treatment Olumiant could be effective at treating COVID-19 patients.
Apr 09, 2020 - Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
Apr 09, 2020 - Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Apr 08, 2020 - The S&P 500's average daily percentage price change over the past five weeks has been plus or minus 4.8%. This explains why the Cboe Volatility Index remains elevated at around the 40s.